A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participants.
Br J Clin PharmacolJun 3, 2026 (epub)
Clinical ResearchGastroenterology
Srividya Neelakantan, Christopher Banfield, Kenneth Hung et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1 randomized controlled trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-07261271, a bispecific antibody, in 35 healthy participants. The study found that PF-07261271 was generally safe and well tolerated, with all treatment-emergent adverse events classified as mild to moderate. Notably, the estimated bioavailability for the subcutaneous administration was 48%.
Key findings
- PF-07261271 was generally safe and well tolerated, with all adverse events mild to moderate.
- The estimated bioavailability of PF-07261271 administered subcutaneously was 48%.
- Dose-dependent increases in serum total sTL1A and p40 levels indicated target engagement.
Why it matters
The study highlights the potential of PF-07261271 as a new therapeutic option for inflammatory bowel disease, addressing the need for more effective treatments that target multiple pathways.